Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 72

Results For "RSE"

2076 News Found

BioAge Labs doses first patient in BGE-102 phase 1 trial
Biotech | August 19, 2025

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants


Pfizer’s sickle cell disease candidate fails Phase III trial
News | August 19, 2025

Pfizer’s sickle cell disease candidate fails Phase III trial

Inclacumab was generally well tolerated in THRIVE-131


STEER World achieves 200 kg/hr continuous granulation with patented INTEGRAAL system
News | August 17, 2025

STEER World achieves 200 kg/hr continuous granulation with patented INTEGRAAL system

The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules


QMS Medical Allied Services reports 31.65% rise in Q1 FY26 PAT to Rs. 3.15 Cr
News | August 17, 2025

QMS Medical Allied Services reports 31.65% rise in Q1 FY26 PAT to Rs. 3.15 Cr

The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth


Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs
News | August 16, 2025

Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs

Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs


Glenmark Pharmaceuticals reached $37.75 million settlement in antitrust litigation in US
News | August 12, 2025

Glenmark Pharmaceuticals reached $37.75 million settlement in antitrust litigation in US

Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S


Centrient Pharmaceuticals joins UNGC
Sustainability | August 12, 2025

Centrient Pharmaceuticals joins UNGC

Reinforcing commitment to ethical and sustainable growth


Lupin partners with Sadoz to commercialise Ranibizumab biosimilar
News | August 12, 2025

Lupin partners with Sadoz to commercialise Ranibizumab biosimilar

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A